NCT01818687View on ClinicalTrials.gov

Safety and Tolerability Study of MCI-196

PHASE3TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Chronic Kidney DiseaseNot on DialysisHyperphosphatemiaPaediatric
Interventions
DRUG

colestilan

body surface area equivalent (BSAeq) 3 g/day, 6 g/day, 9 g/day, 12 g/day or 15 g/day

Trial Locations (1)

Unknown

Investigational site, London

Sponsors
All Listed Sponsors
lead

Mitsubishi Tanabe Pharma Corporation

INDUSTRY